Immunovant, Inc. (IMVT)
NASDAQ: IMVT · Real-Time Price · USD
21.27
+0.82 (4.01%)
At close: Feb 21, 2025, 4:00 PM
21.35
+0.08 (0.38%)
After-hours: Feb 21, 2025, 7:49 PM EST
Company Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases.
The company develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, Graves diseases, and warm autoimmune hemolytic anemia.
Immunovant, Inc. is based in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Immunovant, Inc.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 207 |
| CEO | Peter Salzmann |
Contact Details
Address: 320 West 37th Street, 6th Floor New York, New York 10018 United States | |
| Phone | 917 580 3099 |
| Website | immunovant.com |
Stock Details
| Ticker Symbol | IMVT |
| Exchange | NASDAQ |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| CIK Code | 0001764013 |
| CUSIP Number | 45258J102 |
| ISIN Number | US45258J1025 |
| Employer ID | 83-2771572 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Peter Salzmann M.B.A., M.D. | Chief Executive Officer and Director |
| Dr. Frank M. Torti M.B.A., M.D. | Executive Chairperson of the Board |
| Dr. Jay S. Stout Ph.D. | Chief Technology Officer |
| Eva Renee Barnett M.B.A. | Chief Financial Officer |
| Melanie Gloria B.S.N. | Chief Operating Officer |
| Christopher A. Van Tuyl Esq., J.D. | Chief Legal Officer and Corporate Secretary |
| Lauren Schrier M.B.A. | Vice President of Marketing |
| Christine Blodgett | Senior Vice President of Human Resources |
| Dr. William L. Macias M.D., Ph.D. | Chief Medical Officer |
| Andy Deig | Senior Vice President of Strategic Finance |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 14, 2025 | 144 | Filing |
| Feb 11, 2025 | 144 | Filing |
| Feb 6, 2025 | 10-Q | Quarterly Report |
| Feb 6, 2025 | 8-K | Current Report |
| Jan 24, 2025 | 8-K | Current Report |
| Jan 24, 2025 | 424B3 | Prospectus |
| Jan 21, 2025 | D | Notice of Exempt Offering of Securities |
| Jan 15, 2025 | SCHEDULE 13D/A | Filing |
| Jan 14, 2025 | 8-K | Current Report |
| Jan 13, 2025 | 8-K | Current Report |